The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Periostin advances atherosclerotic and rheumatic cardiac valve degeneration by inducing angiogenesis and MMP production in humans and rodents
Open accessAbstract
Valvular heart disease (VHD) is the term given to any disease process involving one or more of the heart valves. The condition can be congenital or acquired, for example as a result of atherosclerosis or rheumatic fever. Despite its clinical importance, the molecular mechanisms underlying VHD remain unknown. We investigated the pathophysiologic role and molecular mechanism of periostin, a protein that plays critical roles in cardiac valve development, in degenerative VHD. Unexpectedly, we found that periostin levels were drastically increased in infiltrated inflammatory cells and myofibroblasts in areas of angiogenesis in human atherosclerotic and rheumatic VHD, whereas periostin was localized to the subendothelial layer in normal valves. The expression patterns of periostin and chondromodulin I, an angioinhibitory factor that maintains cardiac valvular function, were mutually exclusive. In WT mice, a high-fat diet markedly increased aortic valve thickening, annular fibrosis, and MMP-2 and MMP-13 expression levels, concomitant with increased periostin expression; these changes were attenuated in periostin-knockout mice. In vitro and ex vivo studies revealed that periostin promoted tube formation and mobilization of ECs. Furthermore, periostin prominently increased MMP secretion from cultured valvular interstitial cells, ECs, and macrophages in a cell type-specific manner. These findings indicate that, in contrast to chondromodulin I, periostin plays an essential role in the progression of cardiac valve complex degeneration by inducing angiogenesis and MMP production.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Burden of valvular heart diseases: a population-based study
Nkomo, V. T., Gardin, J. M., Skelton, T. N., Gottdiener, J. S., Scott, C. G., & Enriquez-Sarano, M. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69208-8 · Cited by 4,881
Visse, R., & Nagase, H. (2003) · Circulation Research · doi:10.1161/01.res.0000070112.80711.3d · Cited by 4,575
Intensive Lipid Lowering with Simvastatin and Ezetimibe in Aortic Stenosis
Rossebø, A. B., Pedersen, T. R., Boman, K., Brudi, P., Chambers, J. B., Egstrup, K., Gerdts, E., Gohlke-Bärwolf, C., Holme, I., Kesäniemi, Y. A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804602 · Cited by 1,644
Mutations in NOTCH1 cause aortic valve disease
Garg, V., Muth, A. N., Ransom, J. F., Schluterman, M. K., Barnes, R., King, I. N., Grossfeld, P. D., & Srivastava, D. (2005) · Nature · doi:10.1038/nature03940 · Cited by 1,509
A Randomized Trial of Intensive Lipid-Lowering Therapy in Calcific Aortic Stenosis
Cowell, S. J., Newby, D. E., Prescott, R. J., Bloomfield, P., Reid, J., Northridge, D. B., & Boon, N. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043876 · Cited by 1,146
Freeman, R. V., & Otto, C. M. (2005) · Circulation · doi:10.1161/circulationaha.104.486738 · Cited by 1,006
Oh, J., Takahashi, R., Kondo, S., Mizoguchi, A., Adachi, E., Sasahara, R. M., Nishimura, S., Imamura, Y., Kitayama, H., Alexander, D. B., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00597-9 · Cited by 728
Calcific aortic stenosis: an update
Rajamannan, N. M., Bonow, R. O., & Rahimtoola, S. H. (2007) · Nature Clinical Practice Cardiovascular Medicine · doi:10.1038/ncpcardio0827 · Cited by 176
Cited by
The Extracellular Matrix in Ischemic and Nonischemic Heart Failure
Frangogiannis, N. G. (2019) · Circulation Research · doi:10.1161/circresaha.119.311148 · Cited by 520
Matricellular Proteins in Cardiac Adaptation and Disease
Frangogiannis, N. G. (2012) · Physiological Reviews · doi:10.1152/physrev.00008.2011 · Cited by 445
The role of periostin in tissue remodeling across health and disease
Conway, S. J., Izuhara, K., Kudo, Y., Litvin, J., Markwald, R., Ouyang, G., Arron, J. R., Holweg, C. T. J., & Kudo, A. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1494-y · Cited by 421
Self-citationMitral valve disease—morphology and mechanisms
Levine, R. A., Hagége, A. A., Judge, D. P., Padala, M., Dal-Bianco, J. P., Aikawa, E., Beaudoin, J., Bischoff, J., Bouatia-Naji, N., Bruneval, P., et al. (2015) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2015.161 · Cited by 386
Myocardial Extracellular Matrix: An Ever-Changing and Diverse Entity
Rienks, M., Papageorgiou, A.-P., Frangogiannis, N. G., & Heymans, S. (2014) · Circulation Research · doi:10.1161/circresaha.114.302533 · Cited by 366
Metadata
- Authors
- Hakuno, D., Kimura, N., Yoshioka, M., Mukai, M., Kimura, T., Okada, Y., Yozu, R., Shukunami, C., Hiraki, Y., Kudo, A., Ogawa, S., & Fukuda, K.
- Venue
- Journal of Clinical Investigation
- Published
- 2010-07-01
- Volume
- 120
- Issue
- 7
- Pages
- 2292-2306
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W1967872610
- Cited by
- 199
- References
- 8
- FWCI
- 9.81
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Periostin advances atherosclerotic and rheumatic cardiac valve degeneration by inducing angiogenesis and MMP production in humans and rodents. https://app.cochat.ai/papers/10.1172/jci40973
- The paper
- Hakuno, D., Kimura, N., Yoshioka, M., Mukai, M., Kimura, T., Okada, Y., Yozu, R., Shukunami, C., Hiraki, Y., Kudo, A., Ogawa, S., & Fukuda, K. (2010). Periostin advances atherosclerotic and rheumatic cardiac valve degeneration by inducing angiogenesis and MMP production in humans and rodents. Journal of Clinical Investigation. https://doi.org/10.1172/jci40973
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.